Robert Belvís

Prenatal exposure to triptans—alone or in combination with other migraine medications—does not increase the risk of developmental disorders in children up to age 14, according to research published in Neurology. The study is based on data from more than 26,000 pregnancies in a national registry in Norway and includes autism spectrum disorders, language disorders, and attention deficit hyperactivity disorder, among other diagnoses.

An international team of researchers has conducted a meta-analysis of 137 clinical trials involving nearly 90,000 people to assess the migraine efficacy of 17 available drugs. Their conclusions are that four drugs in the triptan group are more effective and cheaper than newer drugs such as gepants or lasmiditan, and that the efficacy of the latter is comparable to that of paracetamol and most anti-inflammatory drugs. The results are published in The BMJ.